Genzyme, JMF, NHGRI, Affy, EIF, Wellcome Trust, Sanger, Perlegen, GlaxoSmithKline, Stratagene, Innogenetics, Third Wave, ABI | GenomeWeb

Genzyme Launches EGFR Mutation Diagnostic

Genzyme said last week in a statement that it had launched a laboratory test to help identify patients likely to respond to some non-small cell lung cancer therapies targeted to the epidermal growth factor receptor.

Some studies have linked EGFR mutations to response to drugs like Iressa and Tarceva, but the link has not been widely accepted, and the US Food and Drug Administration has not changed the label of either drug to recommend testing.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.